Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron Inc. (NASDAQ:LGVN) announced the pricing of its initial public offering (IPO) of 2,660,000 shares at $10.00 each, aiming for $26.6 million in gross proceeds before expenses. The IPO will close on February 17, 2021, with a 30-day option for underwriters to purchase an additional 399,000 shares. Trading on the Nasdaq starts February 12, 2021. The company's lead product, LOMECEL-B™, targets aging-related conditions. The SEC approved the registration statement on February 11, 2021.